Arcis Biotechnology is a technology led company with expertise in the development and commercialisation of fast and simple sample preparation technologies.
Calculus invested in Arcis Biotechnology due to their impressive suite of technologies and the wide range of applications for them.
The company has an extensive patent portfolio covering extraction and preservation of DNA and RNA for downstream processing. Arcis launched Arcis Sample Prep and Arcis DNA blood kit in 2016 with further new product launches planned for 2017. The company has recently been awarded a Biocatalyst feasibility grant to stabilise RNA from urine which is anticipated will lead to a simpler and more convenient diagnostic test for prostate cancer from urine and eliminate the need for an invasive examination.